论文部分内容阅读
目的观察乳腺癌患者中COX-2的表达及其与HER-2/neu表达的关系,分析COX-2表达对乳腺癌患者DFS的影响。方法应用免疫组化方法检测179例原发性乳腺癌患者标本的COX-2表达及HER-2/neu表达。结果共有25例(13.9%)标本中COX-2呈过表达,并且与HER-2/ neu表达(61/179,34.1%)显著相关(P=0.013)。在单因素生存分析中,COX-2过表达与无疾病生存期显著相关(P=0.029),而COX-2与HER-2/neu共表达患者也有无疾病生存期缩短的趋势。但是多因素分析提示,COX-2过表达与无疾病生存期无显著关系(RR 0.907,95%CI 0.309～2.65,P= 0.858)。结论在人类乳腺癌中,COX-2与HER-2/neu存在共表达。而COX-2与HER-2/neu共表达提示预后差。因此,COX-2选择性抑制剂的临床应用可能是乳腺癌患者治疗的一种新策略。
Objective To observe the expression of COX-2 in breast cancer and its relationship with the expression of HER-2 / neu, and to analyze the influence of COX-2 expression on the DFS in patients with breast cancer. Methods The expression of COX-2 and HER-2 / neu in 179 cases of primary breast cancer were detected by immunohistochemistry. Results A total of 25 patients (13.9%) had overexpression of COX-2 and were significantly associated with HER-2 / neu expression (61 / 179,34.1%) (P = 0.013). In univariate survival analysis, COX-2 overexpression was significantly associated with disease-free survival (P = 0.029), while COX-2 and HER-2 / neu co-expression were also associated with shorter disease-free survival. However, multivariate analysis suggested that there was no significant relationship between COX-2 overexpression and disease-free survival (RR 0.907, 95% CI 0.309-2.65, P = 0.858). Conclusions COX-2 and HER-2 / neu are co-expressed in human breast cancer. Co-expression of COX-2 with HER-2 / neu suggests poor prognosis. Therefore, the clinical application of COX-2 selective inhibitors may be a new strategy for the treatment of breast cancer patients.